Ebola virus vaccines – reality or fiction?

References

• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editor. Fields virology. Philadelphia (PA): Lippincott Williams & Wilkins; 2013. p. 923–956.
   Google Scholar
• Volchkova VA, Feldmann H, Klenk HD, et al. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology. 1998;250:408–414.
   PubMed Web of Science ®Google Scholar
• Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011;85:5406–5414.
   PubMed Web of Science ®Google Scholar
• WHO. Ebola virus disease – Democratic Republic of Congo. Disease Outbreak News. Geneva: WHO; 2014.
   Google Scholar
• Bray M, Davis K, Geisbert T, et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178:651–661.
   PubMed Web of Science ®Google Scholar
• Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001;82:1365–1373.
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999;179(Suppl 1):S203–S217.
   PubMed Web of Science ®Google Scholar
• Ebihara H, Zivcec M, Gardner D, et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis. 2013;207:306–318.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8:503–507.
   PubMed Web of Science ®Google Scholar
• Ryabchikova E, Kolesnikova L, Smolina M, et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol. 1996;141:909–921.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bradfute SB, Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009;83:6404–6415.
   PubMed Web of Science ®Google Scholar
• Cross RW, Fenton KA, Geisbert JB, et al. Modeling the disease course of Zaire ebolavirus infection in the Outbred Guinea Pig. J Infect Dis. 2015;212(Suppl 2):S305–S315.
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423–426.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80:171–186.
   PubMed Web of Science ®Google Scholar
• Bradfute SB, Braun DR, Shamblin JD, et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis. 2007;196(Suppl 2):S296–S304.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393–400.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015;212(Suppl 2):S91–S97.
   PubMed Web of Science ®Google Scholar
• Trefry JC, Wollen SE, Nasar F, et al. Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material. Viruses. 2015;7:6739–6754.
   PubMed Web of Science ®Google Scholar
• Hirschberg R, Ward LA, Kilgore N, et al. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop. Viruses. 2014;6:2673–2697.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196(Suppl 2):S430–S437.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Dye JM, Wells JB, et al. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLoS One. 2015;10:e0118881.
   PubMed Web of Science ®Google Scholar
• Marzi A, Halfmann P, Hill-Batorski L, et al. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science. 2015;348:439–442.
   PubMed Web of Science ®Google Scholar
• Herbert AS, Kuehne AI, Barth JF, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013;87:4952–4964.
   PubMed Web of Science ®Google Scholar
• Grant-Klein RJ, Altamura LA, Badger CV, et al. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Hum Vaccin Immunother. 2015;11:1991–2004.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–609.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424:681–684.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129.
   PubMed Web of Science ®Google Scholar
• Marzi A, Murphy AA, Feldmann F, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep. 2016;6:21674.
   PubMed Web of Science ®Google Scholar
• Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest. 2015;125:3241–3255.
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–790.
   PubMed Web of Science ®Google Scholar
• Marzi A, Robertson SJ, Haddock E, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–742.
   PubMed Web of Science ®Google Scholar
• Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013;9:e1003389.
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Neumann G, Lukashevich I, et al. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol. 2001;75:5205–5214.
   PubMed Web of Science ®Google Scholar
• Licata JM, Johnson RF, Han Z, et al. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol. 2004;78:7344–7351.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Aman MJ. Advances in virus-like particle vaccines for filoviruses. J Infect Dis. 2011;204(Suppl 3):S1053–S1059.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Goetzmann JE, Biggins JE, et al. Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci U S A. 2014;111:8873–8876.
   PubMed Web of Science ®Google Scholar
• Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine. 2012;30(Suppl 5):F83–F87.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008;7:175–191.
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246:134–144.
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. Anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003;21:4071–4080.
   PubMed Web of Science ®Google Scholar
• Hitt MM, Graham FL. Adenovirus vectors for human gene therapy. Adv Virus Res. 2000;55:479–505.
   PubMed Web of Science ®Google Scholar
• Richardson JS, Pillet S, Bello AJ, et al. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol. 2013;87:3668–3677.
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 2010;6:e1000904.
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957.
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394–401.
   PubMed Web of Science ®Google Scholar
• Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 2008;3:e3548.
   PubMed Web of Science ®Google Scholar
• Richardson JS, Abou MC, Tran KN, et al. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis. 2011;204(Suppl 3):S1032–S1042.
   PubMed Web of Science ®Google Scholar
• Choi JH, Schafer SC, Zhang L, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9:156–167.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bailey M, Hensley L, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222–4233.
   PubMed Web of Science ®Google Scholar
• Roy S, Zhi Y, Kobinger GP, et al. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J Gen Virol. 2006;87:2477–2485.
   PubMed Web of Science ®Google Scholar
• Halfmann P, Kim JH, Ebihara H, et al. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci U S A. 2008;105:1129–1133.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Skiadopoulos MH, McAuliffe JM, et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol. 2000;74:6821–6831.
   PubMed Web of Science ®Google Scholar
• Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J. 2003;22:394–405.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol. 2007;81:6379–6388.
   PubMed Web of Science ®Google Scholar
• Bukreyev AA, Dinapoli JM, Yang L, et al. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399:290–298.
   PubMed Web of Science ®Google Scholar
• McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003;77:237–244.
   PubMed Web of Science ®Google Scholar
• Blaney JE, Wirblich C, Papaneri AB, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011;85:10605–10616.
   PubMed Web of Science ®Google Scholar
• Willet M, Kurup D, Papaneri A, et al. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J Infect Dis. 2015;212(Suppl 2):S414–S424.
   PubMed Web of Science ®Google Scholar
• Roberts A, Buonocore L, Price R, et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol. 1999;73:3723–3732.
   PubMed Web of Science ®Google Scholar
• Rose NF, Roberts A, Buonocore L, et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74:10903–10910.
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 2001;106:539–549.
   PubMed Web of Science ®Google Scholar
• Marzi A, Feldmann H, Geisbert TW, et al. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef. 2011;S1(4):pii: 2157-2526-S1-004.
   Google Scholar
• Mire CE, Miller AD, Carville A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6:e1567.
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458–5465.
   PubMed Web of Science ®Google Scholar
• Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine – preliminary report. N Engl J Med. 2015. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe – preliminary report. N Engl J Med. 2015;374:1647–1660.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–866.
   PubMed Web of Science ®Google Scholar
• Mire CE, Matassov D, Geisbert JB, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature. 2015;520:688–691.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894–6900.
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4:e5547.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–1898.
   PubMed Web of Science ®Google Scholar
• Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011;204(Suppl 3):S1066–S1074.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83:7296–7304.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Marzi A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7:e2600.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.
   PubMed Web of Science ®Google Scholar
• De Wit E, Marzi A, Bushmaker T, et al. Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis. 2015;21:702–704.
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–1277.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211:549–557.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz NM, Millard M, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:1545–1554.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–313.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Hou L-H, Li J-X, et al. Safety and immunogenicity of a nocel recombinant adenovirus type 5 vector based Ebola vaccine in healthyadults in China: preliminary report of a phase 1, randomized, double-blind, placebo-controlled clinical trial. Lancet. 2015;385:2272–2279.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine – preliminary report. N Engl J Med. 2015;373:775–776.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2015;16:311–320.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
   PubMed Web of Science ®Google Scholar
• Huttner A, Dayer J-A, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–1166.
   PubMed Web of Science ®Google Scholar
• Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32:5722–5729.
   PubMed Web of Science ®Google Scholar
• Falzarano D, Feldmann H. Vaccines for viral hemorrhagic fevers–progress and shortcomings. Curr Opin Virol. 2013;3:343–351.
   PubMed Web of Science ®Google Scholar
• Jones MEB, Schuh AJ, Amman BR, et al. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses. 2015;7:3420–3442.
   PubMed Web of Science ®Google Scholar
• Vos A, Pommerening E, Neubert L, et al. Safety studies of the oral rabies vaccine SAD B19 in striped skunk (Mephitis mephitis). J Wildl Dis. 2002;38:428–431.
   PubMed Web of Science ®Google Scholar